These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 25177920)

  • 21. The synthetic antimicrobial peptide pexiganan and its nanoparticles (PNPs) exhibit the anti-helicobacter pylori activity in vitro and in vivo.
    Zhang XL; Jiang AM; Ma ZY; Li XB; Xiong YY; Dou JF; Wang JF
    Molecules; 2015 Mar; 20(3):3972-85. PubMed ID: 25738539
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Eradication of Helicobacter pylori: Past, present and future.
    Lopes D; Nunes C; Martins MC; Sarmento B; Reis S
    J Control Release; 2014 Sep; 189():169-86. PubMed ID: 24969353
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preparation and evaluation of anti-Helicobacter pylori efficacy of chitosan nanoparticles in vitro and in vivo.
    Luo D; Guo J; Wang F; Sun J; Li G; Cheng X; Chang M; Yan X
    J Biomater Sci Polym Ed; 2009; 20(11):1587-96. PubMed ID: 19619399
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Formulation and evaluation of stomach-specific amoxicillin-loaded carbopol-934P mucoadhesive microspheres for anti-Helicobacter pylori therapy.
    Patel JK; Chavda JR
    J Microencapsul; 2009 Jun; 26(4):365-76. PubMed ID: 18720199
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Floating microspheres bearing acetohydroxamic acid for the treatment of Helicobacter pylori.
    Umamaheshwari RB; Jain S; Bhadra D; Jain NK
    J Pharm Pharmacol; 2003 Dec; 55(12):1607-13. PubMed ID: 14738585
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted delivery of a short antimicrobial peptide (CM11) against Helicobacter pylori gastric infection using concanavalin A-coated chitosan nanoparticles.
    Moosazadeh Moghaddam M; Bolouri S; Golmohammadi R; Fasihi-Ramandi M; Heiat M; Mirnejad R
    J Mater Sci Mater Med; 2023 Aug; 34(9):44. PubMed ID: 37650975
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of chitosan/heparin nanoparticle-encapsulated cytolethal distending toxin for gastric cancer therapy.
    Lai CK; Lu YL; Hsieh JT; Tsai SC; Feng CL; Tsai YS; Tsai PC; Su HL; Lin YH; Lai CH
    Nanomedicine (Lond); 2014 May; 9(6):803-17. PubMed ID: 24024568
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Genetic type of Helicobacter pylori and the efficacy of eradication therapy].
    Parzecka M; Szaflarska-Popławska A; Mierzwa G; Gorzkiewicz M; Łuczak S; Grzybowski T
    Pol Merkur Lekarski; 2009 Feb; 26(152):105-9. PubMed ID: 19388513
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New Silver(I) Coordination Compound Loaded into Polymeric Nanoparticles as a Strategy to Improve
    Almeida Furquim de Camargo B; Soares Silva DE; Noronha da Silva A; Campos DL; Machado Ribeiro TR; Mieli MJ; Borges Teixeira Zanatta M; Bento da Silva P; Pavan FR; Gallina Moreira C; Resende FA; Menegário AA; Chorilli M; Vieira de Godoy Netto A; Bauab TM
    Mol Pharm; 2020 Jul; 17(7):2287-2298. PubMed ID: 32515970
    [No Abstract]   [Full Text] [Related]  

  • 30. Chitosan-hyaluronic acid nanoparticles loaded with heparin for the treatment of asthma.
    Oyarzun-Ampuero FA; Brea J; Loza MI; Torres D; Alonso MJ
    Int J Pharm; 2009 Nov; 381(2):122-9. PubMed ID: 19467809
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of Helicobacter pylori eradication on incidence of gastric cancer in human and animal models: underlying biochemical and molecular events.
    Kabir S
    Helicobacter; 2009 Jun; 14(3):159-71. PubMed ID: 19702845
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lactoferrin and desferrioxamine are ineffective in the treatment of Helicobacter pylori infection and may enhance H. pylori growth and gastric inflammation in mice.
    Huynh HQ; Campbell MA; Couper RT; Tran CD; Lawrence A; Butler RN
    Lett Appl Microbiol; 2009 May; 48(5):517-22. PubMed ID: 19187488
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mucosal barrier defects in gastric intestinal metaplasia: in vivo evaluation by confocal endomicroscopy.
    Ji R; Zuo XL; Yu T; Gu XM; Li Z; Zhou CJ; Li YQ
    Gastrointest Endosc; 2012 May; 75(5):980-7. PubMed ID: 22325805
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of sucralfate on antibiotic therapy for Helicobacter pylori infection in mice.
    Watanabe K; Murakami K; Sato R; Kashimura K; Miura M; Ootsu S; Miyajima H; Nasu M; Okimoto T; Kodama M; Fujioka T
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4582-8. PubMed ID: 15561829
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of probiotics and triple eradication therapy on the cyclooxygenase (COX)-2 expression, apoptosis, and functional gastric mucosal impairment in Helicobacter pylori-infected Mongolian gerbils.
    Brzozowski T; Konturek PC; Mierzwa M; Drozdowicz D; Bielanski W; Kwiecien S; Konturek SJ; Stachura J; Pawlik WW; Hahn EG
    Helicobacter; 2006 Feb; 11(1):10-20. PubMed ID: 16423085
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Helicobacter pylori (H. pylori) infection in coronary artery disease: influence of H. pylori eradication on coronary artery lumen after percutaneous transluminal coronary angioplasty. The detection of H. pylori specific DNA in human coronary atherosclerotic plaque.
    Kowalski M
    J Physiol Pharmacol; 2001 Aug; 52(1 Suppl 1):3-31. PubMed ID: 11795863
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel gastroretentive porous microparticle for anti-Helicobacter pylori therapy: preparation, in vitro and in vivo evaluation.
    Hao S; Wang Y; Wang B; Zou Q; Zeng H; Chen X; Liu X; Liu J; Yu S
    Int J Pharm; 2014 Mar; 463(1):10-21. PubMed ID: 24406672
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibacterial self-assembled nanodrugs composed of berberine derivatives and rhamnolipids against Helicobacter pylori.
    Shen Y; Zou Y; Chen X; Li P; Rao Y; Yang X; Sun Y; Hu H
    J Control Release; 2020 Dec; 328():575-586. PubMed ID: 32946873
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Helicobacter pylori: microbiology and interactions with gastrointestinal microflora.
    Dzierzanowska-Fangrat K; Dzierzanowska D
    J Physiol Pharmacol; 2006 Sep; 57 Suppl 3():5-14. PubMed ID: 17033102
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of the effects of Helicobacter pylori eradication therapy on gastric antral epithelial hyperproliferation: a prospective six-month follow-up study.
    Demiray M; Gulten M; Manavoglu O; Evrensel T; Ulukaya E; Yerci O; Kanat O; Kurt E; Arslan M; Gonullu G; Demiray H; Gulten T; Memik F
    Hepatogastroenterology; 2004; 51(59):1531-5. PubMed ID: 15362794
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.